prasugrel news from FiercePharma
NewsSetback for Lilly, gain for Plavix?
SPOTLIGHT: Setback for Lilly, gain for Plavix?When FDA delayed its decision on Eli Lilly's clot-buster prasugrel, a.k.a. Effient, it sliced at least three months off the time Lilly might have to win... Read more...
| Press ReleasesFDA Continues to Review Prasugrel New Drug ApplicationFDA Continues to Review Prasugrel New Drug Application TOKYO and INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- Daiichi Sankyo Company, Limited, (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) Read more >> FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, PrasugrelFDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel Companies confirm the start of TRILOGY ACS clinical trial to study Prasugrel against Clopidogrel in Read more >> FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrelFDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel Investigational antiplatelet agent submitted for treatment of patients with acute coronary syndrome being managed with Read more >> Daiichi Sankyo, Lilly Submit NDA for Investigational Antiplatelet Drug, Prasugrel, to FDADaiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration If Approved for Marketing in the United States, Trade Name Read more >> PRESS RELEASE: In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack Investigational compound reduces risk of major cardiovascular events by 19 Read more >> |
Get more prasugrel coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
